fashion -WSS

fashion

author：hotspot 2025-09-03 15:20:12 - browse：7888

What happens when an approved drug doesn’t work? Why don’t patients want gene therapy? And is MASH still a big deal?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease.

For more on what we cover, here’s more on Amylyx; here’s the story on hemophilia gene therapy; here’s the news on Madrigal Pharmaceuticals’ drug for MASH; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Scrutiny of post

Wikipedia

knowledge

WSS

Histogen: Failed biotech offers rare public look inside

For longer

Why Charlie Gard's case is so disturbing to Americans

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Making the case for fair compensation in clinical trials

Phenylephrine and the overlooked value of the placebo effect

focus

fashion

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Why Charlie Gard's case is so disturbing to Americans

Virginia high school admissions case could be legal follow

Citing H5N1 threat, CDC urges peak flu monitoring this summer

The cancer drug shortage isn’t new — and neither are the solutions

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Heart attack and stroke risk calculators need revising

Listen: More tumult at BIO & coercive care for sickle cell patients

Cancer drug shortages should be causing more outrage

At flashy new research hub, AstraZeneca lays out ambitious growth goals

explore

Was Amgen transparent enough on FDA's concern on cancer drug?

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

AI can decode, harness the power of the humane immune system

Why age limits for politicians are a terrible idea

Bird flu surveillance in wastewater gets boost from consortium

Senate panel eyes new effort on drug shortages

explore

Wikipedia

knowledge

hotspot